# A university cyclotron network with shared regulatory files for new tracers

Source: https://onco.cc/ideas/idea-fund-academic-radiopharma-pipeline/  
OnCo record `idea-fund-academic-radiopharma-pipeline` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Most new cancer imaging agents and radioactive drugs start in university hospitals. A network sharing production, quality files and regulatory paperwork would get them into multi-centre trials years faster.

## Summary

Academic radiopharmacy has repeatedly produced the agents the field now runs on (PSMA ligands and FAPI tracers from Heidelberg, DOTATATE from Basel and Rotterdam) but each centre re-creates production, quality control and regulatory documentation. A funded network of university cyclotrons and radiopharmacies would share drug master files, validated synthesis modules, GMP quality systems and a common clinical trial application template, so a tracer validated in one centre can be adopted in ten within months. It would also provide isotope purchasing at scale (gallium-68 generators, lutetium-177, actinium-225 allocation) for academic trials.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: A shared network reduces the time from first-in-human of an academic tracer or radioligand to a five-centre trial from the current several years to under eighteen months, and doubles the number of academic radiopharmaceuticals entering multi-centre trials within four years.
- Rationale: PSMA PET spread globally because academic centres shared precursors and methods informally; formalising that with shared regulatory files removes the largest delay. Germany's and the Netherlands' academic radiopharmacy networks demonstrate feasibility within a country.
- Proposed test: Fund a ten-centre network with a shared master file for two agents and measure time to multi-centre trial start and centres activated compared with agents developed without the network.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008): https://doi.org/10.1038/453840a

## Connected records

- ideas: [A phase 0 fund to test academic compounds in humans with microdoses and imaging](https://onco.cc/ideas/idea-fund-phase-zero-fund/), [FAP theranostics as a pan-cancer stromal strategy](https://onco.cc/ideas/idea-fap-theranostics-pancancer/)
- roadmaps: [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://onco.cc/roadmaps/radiopharma-roadmap/)
- technologies: [FAPI PET](https://onco.cc/technologies/fapi-pet/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/)
- institutions: [German Cancer Research Center (DKFZ)](https://onco.cc/institutions/dkfz/), [Heidelberg University Hospital / NCT / DKFZ](https://onco.cc/institutions/heidelberg-nct/), [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- people: [Frederik Giesel](https://onco.cc/people/frederik-giesel/), [Michael Hofman](https://onco.cc/people/hofman-michael/), [Uwe Haberkorn](https://onco.cc/people/uwe-haberkorn/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [The valley of death between lab and product](https://onco.cc/bottlenecks/b-translational-valley/)
- key papers: [Translational research: crossing the valley of death](https://onco.cc/key-papers/paper-butler-nature/)

---
JSON: https://onco.cc/api/v1/entities/idea-fund-academic-radiopharma-pipeline.json